The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical significance of CA125 in unresectable pancreatic cancer treated with first-line chemotherapy.
 
Iori Motoo
Honoraria - Lilly Japan
 
Takayuki Ando
Honoraria - Bristol-Myers Squibb Company; DAIICHI SANKYO COMPANY, LIMITED.; Lilly Japan; Merck; Miyarisan pharmaceutical; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED. (Inst); Nippon Kayaku (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst)
 
Satoshi Yuki
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Merck; MSD K.K; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Ken Ito
No Relationships to Disclose
 
Akira Ueda
No Relationships to Disclose
 
Yosuke Kito
Honoraria - Daiichi Sakyo; Merck; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
 
Miho Sakumura
No Relationships to Disclose
 
Shinya Kajiura
Speakers' Bureau - DAIICHI SANKYO COMPANY, LIMITED; Kyowa Kirin Co., Ltd.; Lilly Japan; Ono Pharmaceutical; Shionogi
 
Jun Matsuno
No Relationships to Disclose
 
Yoshifumi Nakamura
No Relationships to Disclose
 
Yuma Inoue
No Relationships to Disclose
 
Nobuhiko Hayashi
No Relationships to Disclose
 
Ayumu Hosokawa
Honoraria - Chugai Pharma; Daiichi Sankyo; Eisai; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Chugai Pharma (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Kazuto Shibuya
No Relationships to Disclose
 
Haruyoshi Tanaka
No Relationships to Disclose
 
Mina Fukasawa
No Relationships to Disclose
 
Tsutomu Fujii
Honoraria - Asahi Kasei; Chugai Pharma; Covidien/Medtronic; Daiichi Sankyo; EA Pharma; Johnson & Johnson; Kaken Pharmaceutical; Lilly; Miyarisan pharmaceutical; Otsuka; Taiho Pharmaceutical; TERUMO; Tsumura & Co.
Research Funding - Asahi Kasei (Inst); Chugai Pharma (Inst); Covidien/Medtronic (Inst); Daiichi Sankyo (Inst); EA Pharma (Inst); Johnson & Johnson (Inst); Kaken Pharmaceutical (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Miyarisan pharmaceutical (Inst); MSD (Inst); Otsuka (Inst); Pfizer (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TERUMO (Inst); Tsumura & Co. (Inst)
 
Ichiro Yasuda
No Relationships to Disclose